OncBioMune to Present Abstract on Clinical Trial of Novel Prostate Cancer Vaccine at American Association of Cancer Research Special Conference
BATON ROUGE, LA–(August 29, 2017) – OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (“OncBioMune” or the “Company”), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a proprietary cancer vaccine technology and commercialization of a portfolio of products internationally, is pleased to announce that Dr. Jonathan Head, Chief Executive Officer and Chairman at OncBioMune, will be presenting an abstract at the upcoming American Association of Cancer Research (AACR) Special Conference taking place October 1-4, 2017 at the Boston Marriott Copley Place in Boston, MA.
At the AACR Conference on Tumor Immunology and Immunotherapy, Dr. Head will present an abstract titled, “Preliminary results of a Phase 1a clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer vaccine in PSA defined biochemical recurrent prostate cancer patients.” On August 24, 2017, the Company announced that the final patient in the Phase 1a portion of the trial had completed treatment of ProscaVax, OncBioMune’s novel therapeutic prostate cancer vaccine. Per protocol, the patient will be evaluated 30 days post-treatment for the primary endpoint of determining safety and tolerability of the vaccine, with a secondary endpoint of signs of efficacy. To date, ProscaVax has demonstrated a strong safety profile, with no dose limited adverse events related to the vaccine reported in the study.
“ProscaVax is a very promising treatment addressing an area of unmet medical need in prostate cancer,” commented Dr. Head. “Given all the industry attention immunotherapies are receiving, I suspect that there will continue to be significant interest in the latest data from our study. I look forward to the opportunity to network with peers and discuss ProscaVax at AACR’s special conference.”
Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.
About OncBioMune Pharmaceuticals, Inc.
OncBioMune Pharmaceuticals is a revenue-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, including a proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. OncBioMune is also involved in drug development and commercialization internationally through our wholly-owned subsidiary, OncBioMune México, S.A. De C.V. Our lead pipeline product, ProscaVax™, is scheduled to commence two, separate mid-stage clinical trials in 2017: a Phase 2 for early-stage prostate cancer at a major Northwest U.S. university cancer research hospital and a Phase 2/3 study in Mexico for late-stage prostate cancer patients. OncBioMune has a portfolio of targeted and licensed therapies, some of which are biosimilars and generics to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals’ actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals’ need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical’s vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
Contact:
OncBioMune Pharmaceuticals, Inc.
Andrew Kucharchuk
President and Chief Financial Officer
akucharchuk@oncbiomune.com
http://oncbiomune.com/2017/08/29/oncbiomune-t...onference/
BATON ROUGE, LA–(August 29, 2017) – OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (“OncBioMune” or the “Company”), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a proprietary cancer vaccine technology and commercialization of a portfolio of products internationally, is pleased to announce that Dr. Jonathan Head, Chief Executive Officer and Chairman at OncBioMune, will be presenting an abstract at the upcoming American Association of Cancer Research (AACR) Special Conference taking place October 1-4, 2017 at the Boston Marriott Copley Place in Boston, MA.
At the AACR Conference on Tumor Immunology and Immunotherapy, Dr. Head will present an abstract titled, “Preliminary results of a Phase 1a clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer vaccine in PSA defined biochemical recurrent prostate cancer patients.” On August 24, 2017, the Company announced that the final patient in the Phase 1a portion of the trial had completed treatment of ProscaVax, OncBioMune’s novel therapeutic prostate cancer vaccine. Per protocol, the patient will be evaluated 30 days post-treatment for the primary endpoint of determining safety and tolerability of the vaccine, with a secondary endpoint of signs of efficacy. To date, ProscaVax has demonstrated a strong safety profile, with no dose limited adverse events related to the vaccine reported in the study.
“ProscaVax is a very promising treatment addressing an area of unmet medical need in prostate cancer,” commented Dr. Head. “Given all the industry attention immunotherapies are receiving, I suspect that there will continue to be significant interest in the latest data from our study. I look forward to the opportunity to network with peers and discuss ProscaVax at AACR’s special conference.”
Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.
About OncBioMune Pharmaceuticals, Inc.
OncBioMune Pharmaceuticals is a revenue-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, including a proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. OncBioMune is also involved in drug development and commercialization internationally through our wholly-owned subsidiary, OncBioMune México, S.A. De C.V. Our lead pipeline product, ProscaVax™, is scheduled to commence two, separate mid-stage clinical trials in 2017: a Phase 2 for early-stage prostate cancer at a major Northwest U.S. university cancer research hospital and a Phase 2/3 study in Mexico for late-stage prostate cancer patients. OncBioMune has a portfolio of targeted and licensed therapies, some of which are biosimilars and generics to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals’ actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals’ need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical’s vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
Contact:
OncBioMune Pharmaceuticals, Inc.
Andrew Kucharchuk
President and Chief Financial Officer
akucharchuk@oncbiomune.com
http://oncbiomune.com/2017/08/29/oncbiomune-t...onference/
